Xtl Biopharma Stock Analysis

XTLB -  USA Stock  

USD 3.50  0.06  1.69%

The current indifference towards the small price fluctuations of Xtl Biopharma ADR may raise some interest from investors as it is trading at a share price of 3.50 on 77,500 in trading volume. The company management teams did not add any value to Xtl Biopharma ADR investors in July. However, most investors can still diversify their portfolios with Xtl Biopharma ADR to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.0. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Xtl Biopharma ADR partners.
Check out Your Current Watchlist.

Search Stock Analysis 

The Xtl Biopharma stock analysis report makes it easy to digest most publicly released information about Xtl Biopharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Xtl Biopharma Stock analysis module also helps to analyze the Xtl Biopharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Xtl Biopharma Stock Analysis Notes

About 19.0% of the company outstanding shares are owned by insiders. The book value of Xtl Biopharma was at this time reported as 0.8. The company recorded a loss per share of 0.5. Xtl Biopharma ADR had not issued any dividends in recent years. The entity had 1:10 split on the 10th of February 2017. XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. Xtl Biopharma is traded on NASDAQ Exchange in the United States. For more information please call Joshua Levine at 972 3 611 6600 or visit http://www.xtlbio.com.

Xtl Biopharma ADR Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Xtl Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Xtl Biopharma ADR or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Xtl Biopharma ADR has very high historical volatility over the last 90 days
Xtl Biopharma ADR has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 1.97 M. Net Loss for the year was (2.84 M) with loss before overhead, payroll, taxes, and interest of (5 K).
Xtl Biopharma ADR currently holds about 3.39 M in cash with (850 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64.
Roughly 19.0% of the company outstanding shares are owned by insiders
Latest headline from www.equities.com: XTLceuticals. falls 2.46 percent to Close at 3.57 on July 28 - Equities.com

Xtl Biopharma ADR Upcoming and Recent Events

Earnings reports are used by Xtl Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Xtl Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2017
Next Earnings Report7th of June 2017
Next Fiscal Quarter End31st of December 2016
Next Fiscal Year End30th of March 2017
Last Quarter Report30th of September 2016
Last Earning Announcement31st of December 2015

Xtl Biopharma Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Xtl Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Xtl Biopharma ADR backward and forwards among themselves. Xtl Biopharma's institutional investor refers to the entity that pools money to purchase Xtl Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Noked Israel LtdCommon Shares198.9 K662 K
Noked Capital LtdCommon Shares198.9 K662 K
Morgan StanleyCommon Shares54 K180 K
Renaissance Technologies LlcCommon Shares38.8 K129 K
Steel Peak Wealth Management LlcCommon Shares14.4 K48 K
Ubs Group AgCommon Shares3.5 K12 K
Proequities IncCommon Shares0.00.0
Note, although Xtl Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Xtl Biopharma Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 19.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Xtl Biopharma's market, we take the total number of its shares issued and multiply it by Xtl Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (7.91) % which means that it has lost $7.91 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (49.88) %, meaning that it created substantial loss on money invested by shareholders. Xtl Biopharma management efficiency ratios could be used to measure how well xtl biopharma adr manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 31st of July, Xtl Biopharma maintains the Market Risk Adjusted Performance of 0.1616, downside deviation of 4.68, and Mean Deviation of 2.83. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xtl Biopharma ADR, as well as the relationship between them. Specifically, you can use this information to find out if the company will indeed mirror its model of past data patterns, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Xtl Biopharma ADR, which can be compared to its rivals. Please check out Xtl Biopharma ADR variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Xtl Biopharma ADR is priced fairly, providing market reflects its latest price of 3.5 per share. Given that Xtl Biopharma ADR has jensen alpha of 0.1177, we strongly advise you to confirm Xtl Biopharma ADR's prevalent market performance to make sure the company can sustain itself at a future point.

Xtl Biopharma ADR Price Movement Analysis

The output start index for this execution was fifty-nine with a total number of output elements of two. The Moving Average is predictive technique used to analyze Xtl Biopharma ADR price data points by creating a series of averages of different subsets of Xtl Biopharma entire price series. View also all equity analysis or get more info about all moving average overlap studies indicator.

Xtl Biopharma ADR Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xtl Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xtl Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xtl Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Xtl Biopharma Predictive Daily Indicators

Xtl Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Xtl Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Xtl Biopharma Forecast Models

Xtl Biopharma time-series forecasting models is one of many Xtl Biopharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Xtl Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Xtl Biopharma Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Xtl Biopharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Xtl Biopharma shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Xtl Biopharma. By using and applying Xtl Biopharma Stock analysis, traders can create a robust methodology for identifying Xtl Biopharma entry and exit points for their positions.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. Xtl Biopharma is traded on NASDAQ Exchange in the United States.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Xtl Biopharma to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Global Correlations Now


Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module
Check out Your Current Watchlist. Note that the Xtl Biopharma ADR information on this page should be used as a complementary analysis to other Xtl Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Xtl Biopharma Stock analysis

When running Xtl Biopharma ADR price analysis, check to measure Xtl Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xtl Biopharma is operating at the current time. Most of Xtl Biopharma's value examination focuses on studying past and present price action to predict the probability of Xtl Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Xtl Biopharma's price. Additionally, you may evaluate how the addition of Xtl Biopharma to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
The market value of Xtl Biopharma ADR is measured differently than its book value, which is the value of Xtl Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Xtl Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Xtl Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xtl Biopharma's market value can be influenced by many factors that don't directly affect Xtl Biopharma ADR underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xtl Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Xtl Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xtl Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.